Literature DB >> 28935849

Acute myeloid leukemia with mutated nucleophosmin 1: an immunogenic acute myeloid leukemia subtype and potential candidate for immune checkpoint inhibition.

Jochen Greiner1,2, Susanne Hofmann3,4, Michael Schmitt4, Marlies Götz3, Markus Wiesneth5, Hubert Schrezenmeier5, Donald Bunjes3, Hartmut Döhner3, Lars Bullinger3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28935849      PMCID： PMC5709122          DOI： 10.3324/haematol.2017.176461

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia.

Authors:  Jochen Greiner; Yoko Ono; Susanne Hofmann; Anita Schmitt; Elmar Mehring; Marlies Götz; Philippe Guillaume; Konstanze Döhner; Joannis Mytilineos; Hartmut Döhner; Michael Schmitt
Journal:  Blood       Date:  2012-05-16       Impact factor: 22.113

2.  Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut).

Authors:  Jochen Greiner; Vanessa Schneider; Michael Schmitt; Marlies Götz; Konstanze Döhner; Markus Wiesneth; Hartmut Döhner; Susanne Hofmann
Journal:  Blood       Date:  2013-08-08       Impact factor: 22.113

3.  Donor lymphocyte infusion induces polyspecific CD8(+) T-cell responses with concurrent molecular remission in acute myeloid leukemia with NPM1 mutation.

Authors:  Susanne Hofmann; Marlies Götz; Vanessa Schneider; Philippe Guillaume; Donald Bunjes; Hartmut Döhner; Markus Wiesneth; Jochen Greiner
Journal:  J Clin Oncol       Date:  2012-12-17       Impact factor: 44.544

4.  Leukemic stem cells of acute myeloid leukemia patients carrying NPM1 mutation are candidates for targeted immunotherapy.

Authors:  V Schneider; L Zhang; L Bullinger; M Rojewski; S Hofmann; M Wiesneth; H Schrezenmeier; M Götz; U Botzenhardt; T F E Barth; K Döhner; H Döhner; J Greiner
Journal:  Leukemia       Date:  2014-03-28       Impact factor: 11.528

Review 5.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

Review 6.  The emerging role of immune checkpoint inhibition in malignant lymphoma.

Authors:  Ida Hude; Stephanie Sasse; Andreas Engert; Paul J Bröckelmann
Journal:  Haematologica       Date:  2016-11-24       Impact factor: 9.941

7.  Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial.

Authors:  Christoph Röllig; Martin Bornhäuser; Michael Kramer; Christian Thiede; Anthony D Ho; Alwin Krämer; Kerstin Schäfer-Eckart; Hannes Wandt; Mathias Hänel; Hermann Einsele; Walter E Aulitzky; Norbert Schmitz; Wolfgang E Berdel; Matthias Stelljes; Carsten Müller-Tidow; Utz Krug; Uwe Platzbecker; Martin Wermke; Claudia D Baldus; Stefan W Krause; Friedrich Stölzel; Malte von Bonin; Markus Schaich; Hubert Serve; Johannes Schetelig; Gerhard Ehninger
Journal:  J Clin Oncol       Date:  2014-12-29       Impact factor: 44.544

Review 8.  The expanding role of immunotherapy.

Authors:  Juan Martin-Liberal; María Ochoa de Olza; Cinta Hierro; Alena Gros; Jordi Rodon; Josep Tabernero
Journal:  Cancer Treat Rev       Date:  2017-02-11       Impact factor: 12.111

Review 9.  Combination immunotherapy: a road map.

Authors:  Patrick A Ott; F Stephen Hodi; Howard L Kaufman; Jon M Wigginton; Jedd D Wolchok
Journal:  J Immunother Cancer       Date:  2017-02-21       Impact factor: 13.751

10.  Mutational heterogeneity in cancer and the search for new cancer-associated genes.

Authors:  Michael S Lawrence; Petar Stojanov; Paz Polak; Gregory V Kryukov; Kristian Cibulskis; Andrey Sivachenko; Scott L Carter; Chip Stewart; Craig H Mermel; Steven A Roberts; Adam Kiezun; Peter S Hammerman; Aaron McKenna; Yotam Drier; Lihua Zou; Alex H Ramos; Trevor J Pugh; Nicolas Stransky; Elena Helman; Jaegil Kim; Carrie Sougnez; Lauren Ambrogio; Elizabeth Nickerson; Erica Shefler; Maria L Cortés; Daniel Auclair; Gordon Saksena; Douglas Voet; Michael Noble; Daniel DiCara; Pei Lin; Lee Lichtenstein; David I Heiman; Timothy Fennell; Marcin Imielinski; Bryan Hernandez; Eran Hodis; Sylvan Baca; Austin M Dulak; Jens Lohr; Dan-Avi Landau; Catherine J Wu; Jorge Melendez-Zajgla; Alfredo Hidalgo-Miranda; Amnon Koren; Steven A McCarroll; Jaume Mora; Brian Crompton; Robert Onofrio; Melissa Parkin; Wendy Winckler; Kristin Ardlie; Stacey B Gabriel; Charles W M Roberts; Jaclyn A Biegel; Kimberly Stegmaier; Adam J Bass; Levi A Garraway; Matthew Meyerson; Todd R Golub; Dmitry A Gordenin; Shamil Sunyaev; Eric S Lander; Gad Getz
Journal:  Nature       Date:  2013-06-16       Impact factor: 49.962
View more
  10 in total

Review 1.  T cell optimization for graft-versus-leukemia responses.

Authors:  Melinda A Biernacki; Vipul S Sheth; Marie Bleakley
Journal:  JCI Insight       Date:  2020-05-07

Review 2.  Cancer immune therapy for myeloid malignancies: present and future.

Authors:  Morten Orebo Holmström; Hans Carl Hasselbalch
Journal:  Semin Immunopathol       Date:  2018-07-09       Impact factor: 9.623

3.  Systemic Immunotherapy Effective for Refractory Extramedullary Acute Myeloid Leukemia.

Authors:  Mansour Alfayez; Doina Ivan; Naveen Pemmaraju; Naval Daver; Courtney D DiNardo
Journal:  JCO Precis Oncol       Date:  2019-02-06

4.  Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy.

Authors:  Hanna A Knaus; Sofia Berglund; Hubert Hackl; Amanda L Blackford; Joshua F Zeidner; Raúl Montiel-Esparza; Rupkatha Mukhopadhyay; Katrina Vanura; Bruce R Blazar; Judith E Karp; Leo Luznik; Ivana Gojo
Journal:  JCI Insight       Date:  2018-11-02

5.  Association of HLA class I type with prevalence and outcome of patients with acute myeloid leukemia and mutated nucleophosmin.

Authors:  Kateřina Kuželová; Barbora Brodská; Johannes Schetelig; Christoph Röllig; Zdeněk Ráčil; Juliane Stickel Walz; Grzegorz Helbig; Ota Fuchs; Milena Vraná; Pavla Pecherková; Cyril Šálek; Jiří Mayer
Journal:  PLoS One       Date:  2018-12-17       Impact factor: 3.240

6.  Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin.

Authors:  Rupa Narayan; Niclas Olsson; Lisa E Wagar; Bruno C Medeiros; Everett Meyer; Debra Czerwinski; Michael S Khodadoust; Lichao Zhang; Liora Schultz; Mark M Davis; Joshua E Elias; Ron Levy
Journal:  PLoS One       Date:  2019-07-10       Impact factor: 3.240

7.  High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations.

Authors:  Barbora Brodská; Petra Otevřelová; Cyril Šálek; Ota Fuchs; Zdenka Gašová; Kateřina Kuželová
Journal:  Int J Mol Sci       Date:  2019-06-10       Impact factor: 5.923

8.  Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.

Authors:  Wei-Yu Lin; Sarah E Fordham; Eric Hungate; Nicola J Sunter; Claire Elstob; Yaobo Xu; Catherine Park; Anne Quante; Konstantin Strauch; Christian Gieger; Andrew Skol; Thahira Rahman; Lara Sucheston-Campbell; Junke Wang; Theresa Hahn; Alyssa I Clay-Gilmour; Gail L Jones; Helen J Marr; Graham H Jackson; Tobias Menne; Mathew Collin; Adam Ivey; Robert K Hills; Alan K Burnett; Nigel H Russell; Jude Fitzgibbon; Richard A Larson; Michelle M Le Beau; Wendy Stock; Olaf Heidenreich; Abrar Alharbi; David J Allsup; Richard S Houlston; Jean Norden; Anne M Dickinson; Elisabeth Douglas; Clare Lendrem; Ann K Daly; Louise Palm; Kim Piechocki; Sally Jeffries; Martin Bornhäuser; Christoph Röllig; Heidi Altmann; Leo Ruhnke; Desiree Kunadt; Lisa Wagenführ; Heather J Cordell; Rebecca Darlay; Mette K Andersen; Maria C Fontana; Giovanni Martinelli; Giovanni Marconi; Miguel A Sanz; José Cervera; Inés Gómez-Seguí; Thomas Cluzeau; Chimène Moreilhon; Sophie Raynaud; Heinz Sill; Maria Teresa Voso; Francesco Lo-Coco; Hervé Dombret; Meyling Cheok; Claude Preudhomme; Rosemary E Gale; David Linch; Julia Gaal-Wesinger; Andras Masszi; Daniel Nowak; Wolf-Karsten Hofmann; Amanda Gilkes; Kimmo Porkka; Jelena D Milosevic Feenstra; Robert Kralovics; David Grimwade; Manja Meggendorfer; Torsten Haferlach; Szilvia Krizsán; Csaba Bödör; Friedrich Stölzel; Kenan Onel; James M Allan
Journal:  Nat Commun       Date:  2021-10-29       Impact factor: 14.919

Review 9.  Targeted therapy in NPM1-mutated AML: Knowns and unknowns.

Authors:  Rong Wang; Pan Xu; Lin-Lin Chang; Shi-Zhong Zhang; Hong-Hu Zhu
Journal:  Front Oncol       Date:  2022-09-27       Impact factor: 5.738

Review 10.  Current status and future perspectives in targeted therapy of NPM1-mutated AML.

Authors:  Roberta Ranieri; Giulia Pianigiani; Sofia Sciabolacci; Vincenzo Maria Perriello; Andrea Marra; Valeria Cardinali; Sara Pierangeli; Francesca Milano; Ilaria Gionfriddo; Lorenzo Brunetti; Maria Paola Martelli; Brunangelo Falini
Journal:  Leukemia       Date:  2022-08-25       Impact factor: 12.883
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.